PF-573228

目录号:S2013

仅限科研使用

PF-573228 是一种ATP竞争性的FAK抑制剂,无细胞试验中IC50为4 nM,作用于FAK比作用于Pyk2,CDK1/7 和 GSK-3β选择性高~50到250倍。PF-573228 可诱导凋亡。

PF-573228 Chemical Structure

CAS: 869288-64-2

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1562.28 现货
RMB 1201.44 现货
RMB 4669.29 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的PF-573228发表文献72篇:

产品安全说明书

FAK抑制剂选择性比较

相关FAK产品

生物活性

产品描述 PF-573228 是一种ATP竞争性的FAK抑制剂,无细胞试验中IC50为4 nM,作用于FAK比作用于Pyk2,CDK1/7 和 GSK-3β选择性高~50到250倍。PF-573228 可诱导凋亡。
靶点
FAK [1]
(Cell-free assay)
4 nM
体外研究

PF 573228作用于REF52 细胞, PC3 细胞, SKOV-3 细胞, 及L3.6p1 和 F-G, MDCK细胞,抑制FAK Tyr397磷酸化,IC50为30-500 nM。然而, PF 573228 (1 μM) 抑制80% FAK磷酸化,却不抑制细胞生长或凋亡。PF 573228处理细胞,抑制血清或FN-定向迁移,且降低粘着斑转换。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A431 NV36VGZnU2mwYYPlJIF{e2G7 M1rXd54yOCEQvF2= MkXYSG1UVw>? MnX0bY5pcWKrdIOgSmFMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMUGgcm0> MlnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|OUW1PVQoRjF5M{m1OVk1RC:jPh?=
REF52 MXHLbY5ie2ViYYPzZZk> MVj+NVAh|ryP NYTNOWRTTE2VTx?= M1XW[4lvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRlHLJHR6ejN7NzD3bZRpKEmFNUCgc4YhhjFyMDDuUS=> M2npZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{m1OVk1Lz5zN{O5OVU6PDxxYU6=
PC3 NF:2WoNMcW6jc3WgZZN{[Xl? MYf+NVAh|ryP MUXEUXNQ MUnpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKE[DSzDUfZI{QTdid3n0bEBKSzVyIH;mJFExOCCwTR?= M{\Fb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{m1OVk1Lz5zN{O5OVU6PDxxYU6=
SKOV-3 NUj5bI81U2mwYYPlJIF{e2G7 NYr1eGZ4hjFyIN88US=> M4HJbmROW09? MXvpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKE[DSzDUfZI{QTdid3n0bEBKSzVyIH;mJFUxKG6P M4HGbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{m1OVk1Lz5zN{O5OVU6PDxxYU6=
L3.6p1 M3PwPWtqdmG|ZTDhd5NigQ>? NWTTbWJ2hjFyIN88US=> NWfkcXY2TE2VTx?= MoKwbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCIQVugWJlzOzl5IIfpeIghUUN3MDDv[kA{ODBibl2= Mn7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|OUW1PVQoRjF5M{m1OVk1RC:jPh?=
F-G MVvLbY5ie2ViYYPzZZk> MkXwglExKM7:TR?= NE[3UmdFVVOR NWriXVlkcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDGRWshXHm{M{m3JJdqfGhiSVO1NEBw\iB|MDDuUS=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN7NUW5OEc,OTd|OUW1PVQ9N2F-
MDCK NWnPcXVxU2mwYYPlJIF{e2G7 NVTlOWt7hjFyIN88US=> MWXEUXNQ NVTqXWhtcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDGRWshXHm{M{m3JJdqfGhiSVO1NEBw\iB3MECgcm0> M1TjV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{m1OVk1Lz5zN{O5OVU6PDxxYU6=
PC3 MkL4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4jOTlExKM7:TR?= M2HOUWROW09? MoTxd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aD6= NHHYNXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O5OVU6PCd-MUezPVU2QTR:L3G+
REF52 MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M331VVExKM7:TR?= M{n3SWROW09? MmLnd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aD6= MkfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|OUW1PVQoRjF5M{m1OVk1RC:jPh?=
MDCK NVj5U|E{SXCxcITvd4l{KGG|c3H5 NV72RXJtOTBizszN NHTSS4JFVVOR MXTpcoR2[2W|IHHwc5B1d3Orcx?= Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd|OUW1PVQoRjF5M{m1OVk1RC:jPh?=
REF52 NET2SIpCeG:ydH;zbZMh[XO|YYm= MnfPNVAh|ryP MkXKSG1UVw>? NIi0T3FqdmS3Y3XzJIFxd3C2b4Ppdy=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN7NUW5OEc,OTd|OUW1PVQ9N2F-
REF52 NUn3WJBtTnWwY4Tpc44h[XO|YYm= NHO5eooyOCEQvF2= NET5TIRFVVOR NXfF[Yxr[myxY3vzJJNmenWvIHHu[EBHVi2|dHnteYxifGWmIH3p[5JifGmxbh?= NHr4ZlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O5OVU6PCd-MUezPVU2QTR:L3G+
platelet M1rQeWZ2dmO2aX;uJIF{e2G7 M2P5VFEh|ryP MVjEUXNQ MoXkbY5pcWKrdIOgdIxifGWuZYSgZYdoemWpYYTpc44h[W6mIIPwdoVi\GmwZx?= NW[2dpF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVY5ODNpPkG5O|E3QDB|PD;hQi=>
platelet MXzGeY5kfGmxbjDhd5NigQ>? NHLjR5gyKM7:TR?= MVfEUXNQ M4jsfIxm[WS|IITvJIlvcGmkaYTpc44hd2ZiUFHLJIFv\CCDS2S= NVj5cWR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVY5ODNpPkG5O|E3QDB|PD;hQi=>
platelet NWPYVVNFTnWwY4Tpc44h[XO|YYm= NGW2ZnIyKM7:TR?= NH35Uo9FVVOR M3\NXIJtd2OtczDjZYxkcXWvIH3vZoltcXqjdHnvckBidmRiZHXud4Uh\3KjboXs[UB{\WO{ZYTpc44> M4TIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2PFA{Lz5zOUexOlgxOzxxYU6=
4T1 NXPES2t5TnWwY4Tpc44h[XO|YYm= M1XMeGROW09? NWTMXoJt[WKxbHnzbIV{KHSqZTDpcpRmemGldHnvckBj\XS5ZXXuJO6zOyCrboTl[5JqdiCjbnSgWO6zWi2LSR?= Moe4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEC0N|MoRjF7N{SwOFM{RC:jPh?=
MCF7 M4S4RmtqdmG|ZTDhd5NigQ>? MV\+NVAh|ryP MXrEUXNQ Mm\6bY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCIQVugWJlzOzl5IIfpeIghUUN3MDDv[kA1OzBibl2= NIjMdlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO1OFc5OCd-MkCzOVQ4QDB:L3G+
TamR M{nuWWtqdmG|ZTDhd5NigQ>? M2LlVp4yOCEQvF2= M1nLe2ROW09? M1PZSIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRlHLJHR6ejN7NzD3bZRpKEmFNUCgc4YhPTBibl2= NHXTSlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO1OFc5OCd-MkCzOVQ4QDB:L3G+
FasR MV\LbY5ie2ViYYPzZZk> NFvEfm5,OTBizszN NVLxUpB6TE2VTx?= M{LmcIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRlHLJHR6ejN7NzD3bZRpKEmFNUCgc4YhOTNyIH7N M1zYeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{W0O|gxLz5{MEO1OFc5ODxxYU6=
TamR NGjFWXFHfW6ldHnvckBie3OjeR?= MmjsNUDPxE1? MVjEUXNQ MkS2bY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? MoTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|NUS3PFAoRjJyM{W0O|gxRC:jPh?=
FasR MmrHSpVv[3Srb36gZZN{[Xl? M1HJSVEh|ryP MVXEUXNQ MUXpcohq[mm2czDj[YxtKG2rZ4LheIlwdg>? NXvyemZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOVQ4QDBpPkKwN|U1PzhyPD;hQi=>
endothelial cell MVPLbY5ie2ViYYPzZZk> Mo\iOFAhdk1? MYTEUXNQ MUDpcohq[mm2czDINm8zNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKE[DSx?= NEGzTG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxNlQxOid-MkGyNVI1ODJ:L3G+
endothelial cell NV\mfVlITnWwY4Tpc44h[XO|YYm= NIHLZog1OCCwTR?= M{WxcWROW09? MXrpcohq[mm2czDINm8zNWmwZIXj[YQhe3S{ZYPzJIZq[mW{IH\vdo1ifGmxbh?= M2HZeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyOFAzLz5{MUKxNlQxOjxxYU6=
endothelial cell NXXnPGZySXCxcITvd4l{KGG|c3H5 MmL0OFAhdk1? NGD0XmNFVVOR M1HlUIlvcGmkaYTzJIFxd3C2b4Ppdy=> NFzrUZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxNlQxOid-MkGyNVI1ODJ:L3G+
GH3 NVzG[2tUTnWwY4Tpc44h[XO|YYm= MWmzJO69VQ>? NFrqblhFVVOR MlTjbY5kemWjc3XzJGlMMEOjKTDhcZBtcXS3ZHW= MmPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MkW1NVIoRjJzOUK1OVEzRC:jPh?=
GH3 NWLDeIduTnWwY4Tpc44h[XO|YYm= MmDYN{DPxE1? MnXmSG1UVw>? NGfYOXBmdmijbnPld{BDU0OjLXPoZY5v\WxiYXP0bZZqfHl? NIDZSoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOVUyOid-MkG5NlU2OTJ:L3G+
HUVEC NIi0d5pkgXSxdH;4bYNqfHliYYPzZZk> Mn3PglExKM7:TR?= NXvIUmlQTE2VTx?= MkWzbY1x[Wm{czDlcoRwfGinbHnhcEBk\WyuII\pZYJqdGm2eR?= MlXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{WwOVcoRjJ{MEe1NFU4RC:jPh?=
HUVEC MlPnT4lv[XOnIHHzd4F6 NH\pZXE2KM7:TR?= M4TmcmROW09? NY[0fmxlcW6qaXLpeJMhTkGNIHvpcoF{\SCjY4Tpeol1gQ>? NWm5N5BJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|UxPTdpPkKyNFc2ODV5PD;hQi=>
HUVEC NXfhSVB[TnWwY4Tpc44h[XO|YYm= MoLyOUDPxE1? MV\EUXNQ MVvpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{WwOVcoRjJ{MEe1NFU4RC:jPh?=
HUVEC MojpRZBweHSxc3nzJIF{e2G7 NXfMdVFbPSEQvF2= NH;lcHFFVVOR M3:zWIlv\HWlZYOgZZBweHSxc3nz M1\6S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe1NFU4Lz5{MkC3OVA2PzxxYU6=
HUVEC NEDHXJhHfW6ldHnvckBie3OjeR?= NFnBTlg2KM7:TR?= MYTEUXNQ MXjpcZBm\GW|IHXu[I91cGWuaXHsJINmdGxibXnndoF1cW:wIHHu[EBidHSncoOgeIhmKGOnbHz1cIFzKGGldHnuJIN6fG:|a3Xs[ZRwdg>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5NUC1O{c,OjJyN{WwOVc9N2F-
HUVEC MVHGeY5kfGmxbjDhd5NigQ>? MmnoOUDPxE1? M4Ly[mROW09? MkTXZoxw[2u|IFjVWmVEKHOycn;1eIlv\yCxbjDjc4xt[WenbjDJJIdmdHN? M4LJbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe1NFU4Lz5{MkC3OVA2PzxxYU6=
human peripheral blood T cells NYfLfYNmU2mwYYPlJIF{e2G7 M4\OU54yOCEQvF2= NVTBfJM5TE2VTx?= NGq5e2pqdmirYnn0d{B{cXSnLYPw[YNq\mmlIIDoc5NxcG:{eXzheIlwdiCxZjDGRWs> MkGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MkixPFgoRjJ|OUK4NVg5RC:jPh?=
human peripheral blood T cells M{TaSmZ2dmO2aX;uJIF{e2G7 NV7YWoRnhjFyIN88US=> M1T4ZWROW09? NI\2NWpqdXCjaYLzJHREWi2rbnT1Z4VlKFRiY3XscEBud3KyaH;sc4dq[2GuIHPoZY5o\XNiYX7kJIFtfGW{czDhZ5Rqfmm2eTDv[kBTcG:D MlL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MkixPFgoRjJ|OUK4NVg5RC:jPh?=
human peripheral blood T cells MXXGeY5kfGmxbjDhd5NigQ>? NUDjSVBHhjFyIN88US=> M4DifWROW09? NWXTSGFicW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFqDUD23NEBidmRiTFHU MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl{OEG4PEc,OjN7MkixPFg9N2F-
human peripheral blood T cells MofuSpVv[3Srb36gZZN{[Xl? MmDUglExKM7:TR?= MXnEUXNQ Mn\ibY1x[Wm{czDBcpRq\2WwLXTldIVv\GWwdDDUJINmdGxiY3;ubpVo[XSrb36= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl{OEG4PEc,OjN7MkixPFg9N2F-
U-2 OS Mof0dWhVWyCjc4PhfS=> NILxdmxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz NHXtXnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 NWDaVpVSeUiWUzDhd5NigQ>? NG\JfoRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NXHiU2l6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 M{T2PJFJXFNiYYPzZZk> MoHCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 Mmf0dWhVWyCjc4PhfS=> NV;XcXRpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MVXxTHRUKGG|c3H5 M1u2SZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NX2yVFVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH Mn;kdWhVWyCjc4PhfS=> NHK0THZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M4LMUpFJXFNiYYPzZZk> NYKzOmREeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 MWrxTHRUKGG|c3H5 MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MmPBdWhVWyCjc4PhfS=> MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| M3qw[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NVvvTIRWeUiWUzDhd5NigQ>? M3LwRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz MlHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NGi2UVJyUFSVIHHzd4F6 M{XqNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MVPxTHRUKGG|c3H5 NVTpbZFieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> NUHXUnY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NGDiOWVyUFSVIHHzd4F6 NIXKd|FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Assay
Methods Test Index PMID
Western blot cyclin B1 p-FAK / FAK Lamin A / Lamin C 30761269
Immunofluorescence FAK / F-actin Emerin 30761269
Growth inhibition assay Cell viability 30761269
体内研究 在Ctrl-MT小鼠中,通过PF-573228抑制FAK能显著地抑制乳腺肿瘤的发生以及肺癌的转移。相反地,用PF-573228处理MFCKO-MT小鼠则不影响乳腺肿瘤的发生,这可能与这些小鼠中乳腺上皮细胞缺失FAK有关[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

  • 亲和测定:

    纯化的激活FAK激酶结构域(410-689氨基酸)与50 μM ATP, 和每孔 10 μg Glu和Tyr的随机肽 (摩尔比为4:1), 聚(Glu/Tyr) 在激酶缓冲液(50 mM HEPES, pH 7.5, 125 mM NaCl, 48 mM MgCl2) 中反应15分钟。使用按1/2-Log浓度连续稀释的化合物(起始于1 μM的最高浓度)处理磷酸化的聚(Glu/Tyr)。每种浓度按一式三份进行。使用一般的抗磷酸化酪氨酸(PY20)抗体,随后使用辣根过氧化物酶偶联的山羊抗小鼠IgG抗体检测聚(Glu/Tyr)的磷酸化。加入标准的辣根过氧化物酶底物3,3

细胞实验:

[1]

  • Cell lines: REF52 或 PC3 细胞
  • Concentrations: ~10 μM
  • Incubation Time: 3 天
  • Method:

    REF52或PC3细胞按每孔1×104接种在24孔板中,一式三份,24小时后,使用指定浓度的每种抑制剂处理,进行生长实验,持续3天。随后,收集细胞并计数。

动物实验:

[2]

  • Animal Models: Ctrl-MT 和 MFCKO-MT 小鼠
  • Dosages: 5 mg/kg
  • Administration: 口服

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+2% Tween 80+30% PEG 300+ddH2O

5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 491.49
化学式

C22H20F3N5O3S

CAS号 869288-64-2
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
Would you please let me know the detail of how to dissolve PF-573228 (Catalog No.S2013) for in vivo study (oral administration)?

回答:
PF-573228 in 30% PEG400+0.5% Tween80+ 5% Propylene glycol at 30mg/ml is a suspension. If you will use the compound for oral gavage, this suspension is fine for it.